Our results support accumulating evidence that the expression of CCNG2 diminishes as cancer progresses, with the lowest expression of CCNG2 associated with a more advanced stage of astrocytoma. This evidence concerns the gene CCNG2 and astrocytoma (excluding glioblastoma).